jomfp2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma - An Indian experience.
Jiten JaipuriaAnkita JainShashikant GuptaNripesh SadasukhiPriyatham KasaraneniAmitabh SinghKush GuptaGirish SharmaVineet TalwarSudhir Kumar RawalPublished in: Indian journal of cancer (2024)
Sunitinib should be given via the 2/1 schedule in Indian patients.